Astrazeneca Pharma India Ltd

Astrazeneca Pharma India has shown a significant rebound, with a recent adjustment in its evaluation reflecting improved performance metrics. The stock has been added to MarketsMOJO's list, highlighting its strong recovery and positive trend as it trades above key moving averages. This comes amid a contrasting decline in the broader market.

Astrazeneca Pharma India has experienced a positive shift in its stock evaluation, reflecting its recent performance and market position. The stock has been added to MarketsMOJO's list, indicating a revision in its score. Despite mixed signals from moving averages, Astrazeneca continues to outperform its sector.

Astrazeneca Pharma India's stock saw a decline of -5.55% on November 18, 2024, leading to a 'Hold' call by MarketsMOJO. The stock has underperformed the sector by -4.32% and has been on a downward trend for the past three days. However, its moving averages are still higher than its 200 day average. Investors are advised to do their own research before making any investment decisions.

Astrazeneca Pharma India's financial results for the quarter ending September 2024 showed a flat performance with a score of 5 compared to -1 in the previous quarter. The company's dividend per share and net sales have shown positive trends, while operating cash flow and net profit have declined. MarketsMOJO advises holding positions in the company's stock.

Astrazeneca Pharma India's stock has seen a decline of -5.8% on November 14, 2024, underperforming the sector by -5.78%. The stock has been on a consecutive fall for the last 2 days, with a total decline of -8.22%. It is currently higher than its 200 day moving average, but lower than its 5, 20, 50, and 100 day moving averages, indicating a mixed trend. In comparison to the overall market, the stock has seen a -5.14% decline in the last 1 day and a -11.02% decline in the last 1 month.

On November 12, 2024, Astrazeneca Pharma India's stock gained 6.03%, outperforming the sector by 5.59%. Despite high volatility, the stock is currently trading higher than its moving averages and reached an intraday high of Rs 7746.55. MarketsMOJO has given a 'Hold' call for the stock, which has also outperformed the Sensex in both short-term and long-term performance.

Astrazeneca Pharma India's stock price increased by 5.24% on October 29, 2024, outperforming the sector by 6.11%. The stock has been volatile due to market conditions and reached an intraday high of Rs 7512.9. It has also outperformed the Sensex in the past month, but investors are advised to hold and monitor closely.

Astrazeneca Pharma India, a midcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on October 7th, 2024. The stock has been given a 'Hold' rating by MarketsMOJO and is currently trading higher than its moving averages. With a strong performance and potential for growth, it is a company to watch out for.

Astrazeneca Pharma India, a midcap pharmaceutical company, saw a significant increase in its stock price on October 7th, 2024. It closed at Rs 8099.4, gaining 8.72%. The stock has outperformed the sector by 8.36% and maintained a higher position than its moving averages. It has also outperformed the Sensex by a significant margin.

Astrazeneca Pharma India, a leading pharmaceutical company, reached a 52-week high on September 30, 2024, outperforming the sector by 12.43%. The stock has shown a trend reversal and is currently trading higher than its moving averages. With a remarkable growth of 77.23% in the past year, the company continues to be a top player in the Indian market.

Astrazeneca Pharma India, a midcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs 8021.2 on September 30, 2024. The stock is currently rated as 'Hold' by MarketsMOJO, but has outperformed the sector by 10.63%. Its strong performance and trend reversal make it a promising company in the pharmaceutical industry.

Astrazeneca Pharma India's stock showed a positive trend on September 30, 2024, gaining 5.63% and outperforming the sector by 5.44%. The stock reached an intraday high of Rs 7661.7 and is trading above its moving averages. It has also outperformed the Sensex in both 1-day and 1-month performance. MarketsMOJO has given a 'Hold' call for the company's stock.

Astrazeneca Pharma India, a midcap pharmaceutical company, experienced a -5.19% drop in its stock price on September 25, 2024, in line with the sector's performance. Despite this, the company's stock is still trading higher than its moving averages. According to MarketsMOJO, the current stock call for Astrazeneca Pharma India is 'Hold', based on its performance and 1-month growth compared to the Sensex. The company focuses on developing innovative medicines for various diseases and investors should conduct thorough research before making any investment decisions.

Astrazeneca Pharma India, a midcap pharmaceutical company, reached a 52-week high on September 24th, 2024. The stock has been performing well, outperforming the sector by 12.14%. It opened with a gain of 2.24% and has been trading higher than its moving averages. The company's strong financials and growth potential make it a promising player in the market.

Astrazeneca Pharma India, a midcap pharmaceutical company, has seen a surge in its share price, reaching an all-time high on September 24, 2024. The stock is currently rated as a 'Hold' by MarketsMOJO and has outperformed the sector by 11.06%. With a positive trend in its moving averages and a remarkable growth of 65.14% in the past year, the company shows potential for further growth in the pharmaceutical industry.

Astrazeneca Pharma India, a midcap pharmaceutical company, has gained attention in the stock market with its recent performance. On September 24, 2024, the stock closed at Rs 7301.05, a 7.11% increase. The stock is currently trading close to its 52-week high and has outperformed the sector by 6.8%. Its consistent performance and strong presence in the industry make it a promising player in the market.

Astrazeneca Pharma India, a midcap pharmaceutical company, saw a 5.76% increase in its stock on September 6th, 2024, closing at Rs 7275. According to MarketsMOJO, the stock has been given a 'Hold' call and has outperformed the sector by 5.99%. It is currently trading higher than its moving averages and has shown strong and consistent performance in comparison to the overall market.

Astrazeneca Pharma India, a midcap pharmaceutical company, has reported a flat performance in the quarter ending June 2024. The company's dividend per share has consistently grown over the past five years, while net sales and profit after tax have also shown positive trends. However, operating cash flow, profit before tax, and earnings per share have declined. Investors are advised to hold their positions and closely monitor the company's performance.

On August 8th, 2024, Astrazeneca Pharma India's stock price dropped by 6.42%, in line with the sector's performance. Despite this, the stock has been performing well in the long term, with higher moving averages. It also outperformed the Sensex in both short and long term, making it a recommended hold by MarketsMOJO.